Morgan Stanley Reiterates “Equal Weight” Rating for Ascendis Pharma A/S (NASDAQ:ASND)

Morgan Stanley reaffirmed their equal weight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research report report published on Monday, Benzinga reports. Morgan Stanley currently has a $116.00 price objective on the biotechnology company’s stock.

ASND has been the subject of several other reports. Citigroup lifted their price objective on Ascendis Pharma A/S from $146.00 to $182.00 and gave the stock a buy rating in a research report on Thursday, February 8th. Wedbush lifted their price objective on Ascendis Pharma A/S from $207.00 to $225.00 and gave the stock an outperform rating in a research report on Thursday, February 8th. StockNews.com raised Ascendis Pharma A/S from a sell rating to a hold rating in a research report on Monday, December 25th. Wells Fargo & Company lifted their price objective on Ascendis Pharma A/S from $196.00 to $260.00 and gave the stock an overweight rating in a research report on Friday, March 15th. Finally, JPMorgan Chase & Co. lifted their price objective on Ascendis Pharma A/S from $165.00 to $167.00 and gave the stock an overweight rating in a research report on Tuesday, April 2nd. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of Moderate Buy and a consensus target price of $173.25.

Ascendis Pharma A/S Stock Down 1.1 %

Shares of NASDAQ:ASND opened at $143.18 on Monday. The firm has a market cap of $8.34 billion, a P/E ratio of -15.48 and a beta of 0.50. Ascendis Pharma A/S has a 12-month low of $66.03 and a 12-month high of $161.00. The business has a fifty day simple moving average of $149.15 and a 200 day simple moving average of $125.48.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.15) by $0.49. The business had revenue of $148.62 million during the quarter, compared to analyst estimates of $97.02 million. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 180.61%. As a group, equities research analysts expect that Ascendis Pharma A/S will post -4.15 EPS for the current year.

Institutional Trading of Ascendis Pharma A/S

Large investors have recently made changes to their positions in the company. Private Ocean LLC acquired a new position in Ascendis Pharma A/S during the 1st quarter valued at about $36,000. Hennion & Walsh Asset Management Inc. increased its holdings in Ascendis Pharma A/S by 14.3% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 7,034 shares of the biotechnology company’s stock worth $1,063,000 after purchasing an additional 882 shares in the last quarter. GAMMA Investing LLC increased its holdings in Ascendis Pharma A/S by 52.0% during the 1st quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 102 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in Ascendis Pharma A/S by 1.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 16,384 shares of the biotechnology company’s stock worth $2,064,000 after purchasing an additional 159 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in Ascendis Pharma A/S by 3.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 422,854 shares of the biotechnology company’s stock worth $53,258,000 after purchasing an additional 12,881 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.